Revolutionary test spares millions of cancer patients from chemotherapy
Related: Jessie J announces she is cancer free as she reveals she ‘sobbed for hours’
A revolutionary genomic test, Prosigna, could spare millions of breast cancer patients from chemotherapy, a clinical trial has shown.
The Optima trial observed over 4,400 women and men aged 40 or older with hormone-sensitive breast cancer, who would typically receive chemotherapy.
Participants with a low Prosigna score, indicating low gene activity, were treated with hormone therapy alone.
Those with high scores received chemotherapy and hormone therapy.
Results showed that five years after treatment, 93.6 per cent of low-scoring patients treated with hormone therapy alone were alive and recurrence-free, comparable to the 94.8 per cent who also received chemotherapy.
